Residual respiratory disability after successful treatment of pulmonary TB

Taylor, J., Bastos, M.L., Lachapelle-Chisholm, S., Mayo, N.E., Johnston, J. and Menzies, D., 2023. Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysis. EClinicalMedicine, 59. [TB0041]

·       There are an estimated 155 million tuberculosis (TB) survivors worldwide, equating to 1 in every 50 people alive in 2020.

·       Rifampin was approved by the FDA in 1971, and pyrazinamide (PZA) was widely used starting in 1980.

·       Even after successful treatment for pulmonary tuberculosis (PTB), many individuals experience chronic respiratory issues, including abnormal lung function, bronchiectasis, and an increased risk of lung cancer.

·       More than half of all individuals who completed PTB treatment showed abnormal spirometry results.

·       Post-PTB participants showed significantly lower scores on exercise capacity (6MWT) and physical disability due to breathlessness (MRC dyspnea scale) compared to controls.

·       Specifically, 24.7% had activity-limiting dyspnea (MRC score >2), and patients achieved only 78.9% of the predicted distance on the 6-minute walk test.

·       There is a fourfold higher risk of developing lung cancer in post-PTB participants compared to controls.

·       Persistent cavitation, fibrosis, bronchiectasis, and aspergilloma are frequent complications following PTB.

·       PTB is a major cause of worldwide disability, highlighting the importance of prevention and the potential benefits of TB preventive therapy (TPT) beyond mortality.

·       To better estimate the health burden post-PTB treatment, future studies should focus on translating measures of disability into quality-adjusted life years.

·       Research on the determinants of disability could help develop strategies to limit or prevent disability and identify optimal management approaches.


Comments

Popular posts from this blog

Nutritional status in patients with TB and DM

Scientific advances and the end of tuberculosis

Impact of diabetes on tuberculosis and MDRTB susceptibility